Danaher's dividend hike and institutional backing defy its stock slump
Danaher Corporation has seen major shifts in investor confidence despite a dip in its share price. The company recently raised its quarterly dividend, while large institutions have significantly boosted their stakes. These moves come as Danaher continues to deliver strong financial results, even as broader market challenges weigh on its valuation.
Danaher's latest quarterly report exceeded analyst forecasts, with earnings per share reaching $2.23 and revenue hitting $6.84 billion. The company also announced a dividend increase, lifting the quarterly payout from $0.32 to $0.40 per share. Shareholders will mark March 27, 2026, as the ex-dividend date, with payments issued on April 24.
Institutional investors have taken notice. Ameriprise Financial expanded its holdings by over 211% in the last reporting period. Other major players, including CalPERS and Destination Wealth Management, have also grown their positions in the company. Analysts currently rate Danaher's stock as a 'Moderate Buy,' with a consensus price target of around €234 ($253.55). Yet, the share price has faced downward pressure since early 2024. After peaking at roughly $262 in July 2023, it has since fallen to between $220 and $240—a decline of about 10-15%. Factors such as Federal Reserve interest rate hikes, weaker demand in the biotech sector, supply chain disruptions, and broader market downturns in 2024 and 2025 have contributed to the drop.
The next key date for investors is March 27, when Danaher's shares will trade ex-dividend. With institutional backing growing and a higher dividend now in place, the company's financial strength remains evident. However, its stock performance continues to reflect wider economic and sector-specific pressures.
